Segmentation by type classifies services into Genetic Modification, Phenotypic Engineering, Media & Process Optimization, and Scale‑up & Validation. Genetic Modification, encompassing CRISPR, RNAi, and transgene insertion, is the largest contributor, as it underpins most downstream applications and commands higher fees for design, delivery, and validation. Phenotypic Engineering—altering metabolism, signaling pathways, or stress responses—adds value by creating cell lines with tailored functional attributes, supporting both research and therapeutic pipelines. Media & Process Optimization services, which fine‑tune nutrient formulations and culture conditions, represent a niche but growing segment, especially for biomanufacturing where cost‑efficiency is critical. Scale‑up & Validation, involving pilot‑scale runs and regulatory‑grade documentation, completes the service continuum, ensuring that customized lines transition from bench to production without loss of performance. Each type contributes distinct revenue streams, collectively defining the market taxonomy and influencing strategic investment across the Cell Line Customization Service market.